Cemiplimab
About
Therapy type: Immunotherapy
Therapy strategy: PD-1/PD-L1 inhibition
Mappings
NCI Thesaurus: Cemiplimab (coding:ncit:C121540)
RxNorm: cemiplimab (coding:rxcui:2058826, coding:omop:35200783)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed | |
| FDA (2) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR | Non-Small Cell Lung Cancer | Cemiplimab | |
| EMA (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Cemiplimab | |
| EMA (1) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed |